Evaluation for NCI Surgery Branch Clinical Research Protocols

StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 344 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fields
  2. New version filed on ClinicalTrials.gov
  3. 48 versions Re-verified since Feb 12, 2025, no change to tracked fieldsv295-v342
National Cancer Institute (NCI)
962 trials monitored
See 78 trials at risk
Lung Cancer
4,820 trials monitored
See 267 trials at risk
Colorectal Cancer
3,418 trials monitored
See 162 trials at risk
Melanoma
1,097 trials monitored
See 63 trials at risk
and 1 more disease
Background: The National Cancer Institute Surgery Branch (NCI-SB) has developed experimental therapies that involve taking white blood cells from patients' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells back to the patient. Objective: This study will allow patients to under screening and evaluation for participation in NC-SB Protocols. Eligibility: Patients 18 years or older must meet the minimum eligibility criteria for an NCI-SB treatment protocol. Design Patients will undergo testing and evaluations as required by the appropriate NCI-SB treatment protocol.
Trial Details
NCT Number NCT00001823
Lead Sponsor National Cancer Institute (NCI)
Conditions
(from sponsor)		 Synovial Cell Cancer, Melanoma, Colorectal Cancer, Lung Cancer, Bladder Cancer
Related terms Colorectal Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Urinary Bladder Neoplasms
Enrollment 7,000 participants
Start Date
Updated on ClinicalTrials.gov